Pharmaceutical company Sanofi-Synthelabo announced Monday that it was halting the clinical trial of the heart arrhythmia medication dronedarone due to safety concerns. According to the drug maker, 24 patients died while taking dronedarone, compared to 10 in the placebo group. Sanofi was attempting to develop a safer